Study Phase 3

A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Trial Information

Generic NameUstekinumabProduct NameSTELARA®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassImmunosuppressantsCondition StudiedPsoriasisChemical SubgroupsN/APharmacological SubgroupsN/A
Sponsor Protocol NumberCNTO1275PSO3009Enrollment478Data PartnerJohnson & Johnson% Female37.6%Mean/Median Age (Years)45.1% WhiteN/A

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.